Targeted Oncology | Dialogues in Diagnostics
Targeted Oncology | Differential Diagnosis
Targeted Oncology | Case-Base Peer-Perspective

Top Medical News Today

Galeterone Misses PFS Endpoint in Prostate Study, Leading to Trial Discontinuation
The phase III ARMOR 3-SV trial for prostate cancer was not likely to meet its primary endpoint of radiographic progression-free survival (PFS) improvement, the trial’s independent data monitoring committee (DMC) decided, leading to the trial’s discontinuation, according to the manufacturer Tokai Pharmaceuticals.
Cholangiocarcinoma: New Targeted Therapies on the Horizon
An increasing number of investigators are focused on developing therapies specifically for cholangiocarcinoma as rates for the disease are rising. 
Exploring Apalutamide in Patients with High-Risk Prostate Cancer
A study of apalutamide (ARN-509) in patients with high-risk, localized, or locally advanced prostate cancer who are receiving primary radiation therapy is hoping to reduce the risk of metastasis and death from prostate cancer for these high-risk patients, according to the study’s global principal investigator, Howard M. Sandler, MD.
Expert Details Progression of Immunotherapy Agents in Prostate Cancer
There have been limited successes made in immunotherapy in the treatment of patients with prostate cancer so far, but progress is being made, explains Akash Patnaik, MD, PhD, an assistant professor of Medicine at the University of Chicago Medicine.
CHMP Recommends Liposomal Irinotecan in Pancreatic Cancer Following Positive Findings
The Committee for Medicinal Products for Human Use has recommended the approval of pegylated liposomal irinotecan in combination with fluorouracil and leucovorin for patients with metastatic pancreatic adenocarcinoma following progression on a gemcitabine-based therapy.
Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering, discusses some of the emerging therapies for patients with ER-positive metastatic breast cancer.
View More >


Nivolumab Given Priority Review for Head and Neck Cancer
Nivolumab Given Priority Review for Head and Neck Cancer
The FDA has agreed to review nivolumab under an accelerated timeframe for its potential as a treatment for patients with previously treated metastatic or recurrent squamous cell carcinoma of the head and neck.
Understanding the Future of Immunotherapy in Melanoma
While there have been many recent advances in the field of melanoma regarding immunotherapy, there is still much more to come, says Antoni Ribas, MD, PhD.
Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLL
With nearly a dozen new PI3K and BTK inhibitors currently in development, it is challenging to know which therapies are truly "next-generation" agents and which are "me too" products.
Shortcomings in SIRFLOX Design May Have Skewed PFS Findings
Shortcomings in the SIRFLOX study may have confounded the main findings, as the trial seemed plagued by a large number of confounding factors and a shifting trial design.
Novel Agent BION-1301 May Block Multiple Myeloma Cell Proliferation
BION-1301 may block multiple myeloma cell proliferation and reduce drug resistance and immunosuppression in the tumor microenvironment.